Analyses on the Impact of Tumor Burden at Progression and Changes in IMDC Risk Scores in the CLEAR Trial Prognostic Insights in Advanced RCC With Lenvatinib Plus Pembrolizumab

Experts discuss insights from the CLEAR trial on lenvatinib plus pembrolizumab, focusing on depth of response and clinical outcomes in advanced renal cell carcinoma.

Experts discuss the impact of tumor burden on postprogression survival, exploring strategies to optimize responses in renal cell carcinoma.

Experts discuss optimizing renal cell carcinoma treatment strategies across the care continuum, from initial response to long-term outcomes.

Experts discuss the clinical implications from CLEAR post hoc analyses, focusing on IMDC risk assessments and sequencing strategies.

Experts discuss risk score stability and post lenvatinib plus pembrolizumab treatment selection in renal cell carcinoma.

Experts share clinical pearls on synthesizing risk assessment and response patterns in the management of advanced renal cell carcinoma.

Experts discuss their approaches to first-line renal cell carcinoma treatment selection, comparing immunotherapy (IO)-IO vs IO-tyrosine kinase inhibitor strategies.

Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.